ArticleCancers2025

Efficacy and Safety of Nivolumab Plus Ipilimumab for Metastatic Renal Cell Carcinoma in Patients 75 Years and Older: Multicenter Retrospective Study.

Shimpei Yamashita et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.